Accumulating Data to Optimally Predict Obesity Treatment (ADOPT): Recommendations from the Biological Domain

Michael Rosenbaum, Tanya Agurs-Collins, Molly S. Bray, Kevin D. Hall, Mark Hopkins, Maren Laughlin, Paul S. MacLean, Padma Maruvada, Cary R. Savage, Dana M. Small, and Luke Stoeckel

Background: The responses to behavioral, pharmacological, or surgical obesity treatments are highly individualized. The Accumulating Data to Optimally Predict obesity Treatment (ADOPT) project provides a framework for how obesity researchers, working collectively, can generate the evidence base needed to guide the development of tailored, and potentially more effective, strategies for obesity treatment.

Objectives: The objective of the ADOPT biological domain subgroup is to create a list of high-priority biological measures for weight-loss studies that will advance the understanding of individual variability in response to adult obesity treatments. This list includes measures of body composition, energy homeostasis (energy intake and output), brain structure and function, and biomarkers, as well as biobanking procedures, which could feasibly be included in most, if not all, studies of obesity treatment. The recommended high-priority measures are selected to balance needs for sensitivity, specificity, and/or comprehensiveness with feasibility to achieve a commonality of usage and increase the breadth and impact of obesity research.

Significance: The accumulation of data on key biological factors, along with behavioral, psychosocial, and environmental factors, can generate a more precise description of the interplay and synergy among them and their impact on treatment responses, which can ultimately inform the design and delivery of effective, tailored obesity treatments.

Introduction

Weight loss provokes coordinated changes in multiple energy homeostatic systems which culminate in disproportionately increased energy intake (EI) and decreased energy expenditure (EE) (1,2). The extensive interindividual variability in responses to weight loss (3) and treatments differentially targeting these systems (4,5) suggests that treatment could be improved via better understanding of the biological factors mediating energy balance (6,7).

The NIH-sponsored Accumulating Data to Optimally Predict obesity Treatment (ADOPT) Core Measures Project (8) aims to advance adult obesity medicine in the face of this individual variability in treatment responses (9). ADOPT is designed to provide investigators with tools to generate an evidence base consisting of common measures across the following four domains: behavioral, biological, environmental, and psychosocial, which can enhance interdisciplinary research and advance understanding of the sources of response variability, depicted in the ADOPT Working Model.

The biological domain subgroup of the ADOPT working group was tasked with recommending core measures relevant to the “constructs” of body composition, energy balance, biomarkers, brain structure and function, and biobanking, as previously designated by the full ADOPT working group. The uniform reporting of common measures can increase the impact and generalizability of the combined research body. Further information regarding each construct and measure described below is available at the ADOPT Core Measures Workspace in the Grid-Enabled Measures (GEM) database (https://www.gem-measures.org/workspaces/ADOPT), which is also a venue for discussions that help to build consensus around common measures.

1 Columbia University, Vagelos College of Physicians & Surgeons, New York, New York, USA. Correspondence: Michael Rosenbaum (mr475@cumc.columbia.edu) 2 National Cancer Institute, National Institutes of Health, Rockville, Maryland, USA 3 Department of Nutritional Sciences, University of Texas at Austin, Texas, USA 4 National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA 5 School of Food Science and Nutrition, University of Leeds, Leeds, England 6 School of Medicine, University of Colorado School of Medicine, Aurora, Colorado, USA 7 Center for Brain, Biology and Behavior, Department of Psychology, University of Nebraska, Lincoln, Nebraska, USA 8 Yale University Medical School, New Haven, Connecticut, USA.

Funding agencies: The ADOPT Core Measures Working Group was supported by intramural funding from the following National Institutes of Health: The National Heart, Lung, and Blood Institute, the National Cancer Institute, and the Office of Disease Prevention. The Grid-Enabled Measures Database (GEM) is supported and administered by the National Cancer Institute.

Disclosure: The authors declared no conflict of interest. The views expressed in this paper are those of the authors and do not necessarily represent the positions of the NIH, the DHHS, or the Federal Government.

Received: 17 January 2018; Accepted: 12 February 2018; Published online 23 March 2018. doi:10.1002/oby.22156
Identification of Biological Measures

In an effort to create a list of measures of relevant biological constructs that could be employed across most, if not all, clinical human obesity studies, several factors were considered in the selection of the methods (designated as “measures”) best designed to evaluate each construct given the constraints of human weight-loss trials. These included (1) the strength of the current evidence relating each measure to relevant constructs and weight-loss outcomes, (2) the measure’s validity and reliability, (3) the feasibility of widespread use of the measure, (4) the measure’s burden to investigators (cost, administration, availability) and subjects (time and invasiveness), and (5) the measure’s applicability to small (<50 participants), moderate (50-200 participants), and large (>200 participants) studies.

In many cases, the “gold standard” measures were not the most practical within the feasibility constraints of many weight-loss trials. Recognizing the frequent dichotomy between precision and practicality, we provide two classifications of measures within the constructs. “Recommended” measures are those that should be feasible and cost-effective in all obesity-related clinical trials. “Suggested” measures are those that should be feasible and cost-effective in many, if not most, clinical trials and, if possible, should be performed in addition to the recommended measures. Except as otherwise noted (e.g., for targeted genetic studies), all measures outlined below should be obtained at baseline and at other time points (e.g., during and after an intervention) in each study.

Body Composition

Within the area of body composition, we included both anthropometric and bioelectrical impedance measures to allow for the assessment of body fat content, central versus peripheral fat distribution, and visceral versus subcutaneous fat distribution in a manner that can be integrated across previous and future studies (10). It is likely that this recommendation will change going forward, as more investigators use recommended measures of body fat content (see below).

Anthropometry

Anthropometry includes the assessment of height, weight, and calculated BMI (recommended) as well as central fat mass (FM) and the relative distribution of fat in central and peripheral fat depots by waist and hip circumferences and calculated waist-to-hip ratio (WHR) (recommended). The feasibility of anthropometry permits easy frequent measurement (at least every 1 to 3 months in the initial phases of weight-loss trials), which is necessary to document early responses (1 to 2 months) to surgical (11,12) and nonsurgical (13,14) interventions as predictors of long-term success.

However, together BMI, sex, and age only explain approximately 50% to 60% of the variance in percent body fat as measured by dual energy x-ray absorptiometry (DXA) (suggested), which is the “gold standard” (15), and anthropometry is clearly less accurate than bioelectric impedance spectroscopy (BIS), DXA, magnetic resonance imaging (MRI), and BodPod (see below). The accuracy of BMI is further diminished in participants with increased fractional lean body mass, such as athletes with very high muscle mass, (e.g., weightlifters) (16), or increased fractional FM, such as the elderly. BMI does not assess FM and fat-free mass (FFM), both of which are important determinants of EE and EI, and different interventions may differentially affect body composition (FM and FFM) and weight (16).

It is recommended that both waist circumference and WHR are collected in all adult studies (17) because both the absolute amount of central fat (17,18) and the relative amount of fat distributed in central versus peripheral fat depots (19,20) have been shown to be predictive of multiple adiposity-related comorbidities and may affect intervention response (21-23). Both of these measures have been reported to correlate closely with visceral and subcutaneous adipose tissue measured by DXA (suggested) or MRI (24,25). To minimize variability in WHR, it is critical that investigators utilize uniform landmarks, with waist circumference measured at the iliac crest and hip circumference measured at the level of the trochanters as utilized by the National Center for Health Statistics in National Health and Nutrition Examination Survey studies (26). It should be noted that the abdominal circumference measured at the midpoint between the inferior border of the ribcage and the superior aspect of the iliac crest has been reported to be a better correlate of central adiposity in some studies (27). However, the NIH method is recommended to allow for better comparisons with existing National Health and Nutrition Examination Survey and other data.

Anatomic fat storage

Anthropometry fails to distinguish subcutaneous from visceral fat, which has been reported to be correlated with the risk for metabolic syndrome, cardiovascular disease, and several malignancies (28), and the relative distribution of visceral and subcutaneous fat varies significantly by gender and between ethnic and/or racial groups (29). Specifically, it is recommended that all studies include more direct measures of FM by BIS (30), which is a noninvasive and inexpensive type of bioimpedance to assess body composition that can be utilized in studies of any size or duration. BIS is comparable with the single-frequency devices used in bioimpedance analysis (conventionally denoted as BIA) in terms of subject burden and cost. The multisegmental, multifrequency BIS device allows for the identification of more components of bioimpedance (capacitance, resistance, etc.) than single-frequency bioimpedance analysis devices, and BIS measures of extracellular/intracellular resistance have been reported to be significantly correlated with intraabdominal FM measures by computed tomography scans (31). BIS has also been reported to correlate better with FM than BMI and with visceral and/or intraabdominal fat (measured by MRI) than waist circumference or WHR (32). Overall, BIS has been reported to explain 80% to 90% of the variance in FM and visceral fat and 50% to 55% of the variance in intraabdominal fat by DXA and/or MRI (32,33). Despite the advantages of BIS, it has been reported to underestimate FM and overestimate FFM, especially in males (33), and BIS can be less reliable when the hydration status of FM and FFM are uncertain (e.g., in children, individuals with edema, and postbariatric surgery patients). In addition, there are multiple BIS systems available that have not been crossvalidated. It is therefore essential to always report the exact BIS system utilized.

The addition of BIS will allow for the integration of data from multiple studies and further validation of this approach. Though BIS provides the best option for the assessment of body composition, when balancing the value of the data with the cost and participant burden in large clinical trials, this recommendation does not preclude the use of more accurate or precise suggested measures of body composition such as DXA, MRI, or quantitative magnetic
resonance spectroscopy. It is anticipated that the acquisition of BIS data along with other suggested measures of body composition in some studies will provide a large data set that can be utilized to better define the precision of BIS in different populations.

Energy Balance

The relative long-term constancy of body weight and the overall lack of success of nonsurgical interventions in long-term weight reduction suggests that, at usual weight, EI and output are “coupled” and vary directly to maintain energy stores. Once weight is perturbed, this coupling is lost, and EI and energy output now vary inversely to “defend” previous body energy stores (2,34). There is large interindividual variability in EI and EE (including cardiorespiratory fitness [CRF], which is an important determinant of exercise recommendations) and, of course, adherence before, during, and after weight change (3,23,35-37). A better understanding of this variability is likely to identify certain energy homeostatic phenotypes that are predictive of individualized best practice recommendations.

EE

Total EE (TEE) is composed of resting EE (REE), the thermic effect of feeding (TEF), and nonresting EE (NREE) (38), each of which is likely to change in weight-loss studies. Direct and indirect objective measures for these variables present challenges for large clinical weight-loss trials because of their expense, participant burden, and feasibility. Because of these limitations, it is recommended that measures of TEE and its components be calculated.

Calculated REE should be acquired with the Mifflin-St. Jeor equation (recommended) (39), which is best correlated ($R^2 = 0.80-0.85$) with calorimetric measures of REE (39) and superior to other less-studied or more population-specific equations (40). The following are the Mifflin-St. Jeor equations: for males, $\text{REE (kilocalories per day)} = 10 \times \text{weight (kilograms)} + 6.25 \times \text{height (centimeters)} - 5 \times \text{age (years)} + 5$; for females, $\text{REE (kilocalories per day)} = 10 \times \text{weight (kilograms)} + 6.25 \times \text{height (centimeters)} - 5 \times \text{age (years)} - 161$.

It should be noted that the Mifflin-St. Jeor equation may also have limitations in its generalizability. Equations for individuals who are transgenders, intersex, have abnormal numbers of X or Y chromosomes, or who have undergone or are undergoing surgical or hormonal therapy relevant to gender have not as yet been derived (41). The increasing attention to gender medicine and gender-specific biological variation in human metabolic disease should yield an expanded list of calculations going forward.

In lieu of directly measuring NREE, it is recommended that a questionnaire-based assessment of Physical Activity Level (PAL) be acquired (42). PAL is defined as $\text{TEE/REE}$, and the questionnaire-derived PAL was chosen because of its simplicity, its validation by correlation with PAL measured by calorimetry, and its applicability across multiple studies. This questionnaire provides a self-evaluation of physical activity during work and leisure activities. The calculated REE and PAL can then be used to derive a calculated TEE ($\text{TEE} = \text{PAL} \times \text{REE}$).

The working group readily acknowledges that other direct and indirect measures can provide more accurate and precise measures of TEE, its components, and metabolic adaptation in response to treatment (43) but are not feasible in many weight-loss trials because of the expense and required specialized equipment (38,44). If possible, the calorimetric measurement of REE in the overnight fasted state by using a metabolic cart or room indirect calorimeter to measure rates of carbon dioxide production ($\text{VCO}_2$) and oxygen consumption ($\text{VO}_2$) is suggested. The $\text{VCO}_2/\text{VO}_2$ ratio provides an index of the relative mixture of metabolic fuels being utilized. Similarly, doubly-labeled water can be used to measure TEE in the free-living environment, and whole-room indirect calorimetry chambers can be used to provide robust objective estimates of TEE, NREE, and REE. Though these approaches can also be utilized to acquire TEF with the appropriate feeding study design, TEF is neither recommended nor suggested across all studies because of the necessary complexity of these designs coupled with the relatively small contribution of TEF to TEE and adaptive thermogenesis (3).

EI

Under static conditions of body weight and composition stability, EI must be equal to TEE. EI steady state (recommended) refers to EI when body composition and mass are not changing over time and can be presumed equal to the calculated TEE (45). It should be noted that this does not include or account for variations in diet composition or the possible effects on the partitioning of stored calories (see the body composition section) that might occur, for example, as a result of weight loss with a resistance training component (increased partitioning of stored calories as FFM) versus aerobic training (46). During dynamic periods of weight change ($\text{EI} \neq \text{EE}$), measuring EI is more difficult. Self-reported EI measures have been shown to be inaccurate (47) but changes in EI (recommended) during such periods can be mathematically modeled with measures of EE and body composition dynamics (33). This model has recently been validated against the intake-balance method in a 2-year calorie-restriction experiment in 140 people of varying age and BMI (48), and it requires only baseline anthropometric and demographic information along with repeated body weight measurements over the course of the intervention. There are assumptions underlying this model, such as the stability of REE and PAL. More frequent body weight measurement increases the precision of the calculated changes in EI over time, and physical activity time course data (e.g., from actigraphy measurements) can also be incorporated to account for changes in NREE. The full description of this calculation, including MatLab Code information, can be found at the GEM website (https://www.gem-measures.org/workspaces/ADOPT).

The estimation of the average EI over an extended duration is ideally calculated by using the intake-balance method involving body composition measurements along with repeated TEE measurements by using doubly labeled water (49); these procedures are, unfortunately, impractical for larger weight-loss studies. Depending upon the duration and types of weight-loss intervention, and participant age and gender, calculated EI based on TEE and weight or body composition change has accounted for between 20% and 60% of the variance in EI calculated by using the intake-balance method (suggested) as described above (48).

CRF

CRF varies significantly between individuals and may modify responses to obesity treatment either directly or via compliance with
exercise recommendations (50). CRF is also significantly correlated with mortality and comorbidity risk, independent of body fatness (51). Though the gold standard for CRF is an ergometric VO$_{2\text{max}}$ test, an approximation can be made from resting heart rate or an alternative submaximal fitness test. Resting heart rate was selected as a recommended measure because it is easy and inexpensive to perform and has been reported to explain about 20% of the variance in CRF (52) using multiple different equations and calculations. The 3-minute step test has been reported to explain 50% to 90% of the variance in fitness by treadmill testing but may not be practical for larger studies, and it is therefore suggested rather than recommended (53,54). For subjects who are unable to perform the step test because of orthopedic or fitness issues, a simpler version using a corridor walk may be substituted (55).

### Brain Structure and Function

Obesity-associated alterations in brain structure and function (56,57) have been correlated with weight loss and regain in behavioral and bariatric surgery trials (56,58), with limited data regarding other treatments. Incentive motivation, reward learning, and executive function (including working memory) (58) are the neurocognitive constructs most predictive of treatment outcomes. These functions are largely mediated by the dopaminergic fronto-striatal (reward/motivation), fronto-parietal (executive function), and hippocampal-amygdala (learning and memory) systems, which operate as both independent and interdependent networks (59). Emerging data has also indicated that related neural systems (interoceptive and salience networks) could be important for weight outcome prediction (60).

This manuscript focuses on brain structure and function rather than the affected neurocognitive constructs discussed in the ADOPT psychosocial domain (61). The current gold standard measures are MRI to assess structure and blood oxygen-dependent functional MRI (fMRI) to assess function. FMRI can identify the (1) neural substrates that execute behaviors in response to environmental demands and (2) functionally linked intrinsic neural networks that can be assessed in the absence of external, environmental demands (i.e., resting state fMRI). The measurement of resting-state connectivity is feasible in large multisite studies and, when integrated with other measures (e.g., cognitive, psychosocial, other biomarkers), can define mechanisms and neuropsychological subtypes that may predict responses to treatment (62) even though correlations of resting-state fMRI in specific single brain regions with behaviors are relatively low (63-69).

Because of the cost and burden to both the participants and researchers, resting-state fMRI scans are only suggested when feasible. Analyses of these fMRI data should include the assessment and comparison across several networks representing the neural systems described above. The suggested MRI/fMRI protocol includes (1) anatomical MRI for structure (volume, density, shape, cortical thickness) and to aid in preprocessing of the fMRI data, (2) diffusion MRI (white matter tractography or structural connectivity), and (3) resting-state functional connectivity MRI. Given that resting-state functional connectivity MRI may be sensitive to the internal state, collecting data about the participant’s last meal and the subjective experience of the internal state (hunger, satiety) is suggested (61). Resting-state studies in fasting and fed states will provide insights into brain areas related to meal initiation and cessation. The value of fMRI is significantly increased through the integration with neurocognitive and psychosocial measures (61) and biomarkers of EI (e.g., gut peptides) and EE (e.g., leptin and thyroid hormones) described below.

### Humoral Biomarkers

Biomarkers can provide information about the potential mechanisms by which information regarding nutrient availability, energy stores, and energy balance are communicated to central nervous system tracts regulating energy homeostasis as well as provide valuable insights into adiposity-related comorbidities. Biomarker significance is influenced by whether subjects are at weight homeostasis, are weight-reduced, or are in the process of weight gain or loss. Some of the recommended biomarkers (e.g., leptin) predictably and coordinately change in response to calorie-restricted weight loss in a manner that would elevate appetite and suppress EE (1). Baseline measures for some recommended biomarkers (e.g., leptin, total ghrelin) are predictive of weight regain (70,71) in some, but not all, studies (72). The potential value and/or cost of these measures at baseline, after weight loss, and after a period of weight maintenance is considered high, given the low subject burden (i.e., a blood draw) and commercial availability of the assays.

### Energy homeostasis

A number of adipocyte-derived hormones yield valuable data regarding factors that may affect or represent energy stores and balance. As exemplified by leptin (recommended) (73), response to any intervention may depend upon whether the participant is being treated to promote weight loss or prevent weight regain. Therefore, biochemical assessments relevant to energy balance and/or affecting EI and energy output are extremely relevant.

Leptin is secreted by adipose tissue, reflects both adipose tissue stores and energy balance, and is recommended. At baseline weight, circulating leptin concentrations are directly proportional to FM, while during caloric restriction, the leptin/FM ratio may be severely decreased versus only mildly diminished following weight loss (73). A low ratio of leptin to FM may therefore be an indicator of undernutrition, while an unusually high ratio may suggest leptin resistance.

The measurement of fasting levels of the pancreatic peptide amylin is recommended, not only for its effects on nutrient utilization by inhibition of postprandial glucagon, but also because it reduces EI by promoting satiation and attenuates the disproportionate decline in EE that typically occurs during and following weight loss; it thus serves as a marker of weight response (74). In rodent studies, amylin receptors are located within the brainstem as well in multiple other organs, and exogenous amylin acts synergistically with leptin as well as glucagon-like peptide 1 (GLP-1), peptide YY (PYY), and other anorexiant molecules (75). In human studies, coadministration of amylin with leptin has been shown to enhance weight loss during caloric restriction (76).

Adiponectin, particularly high-molecular-weight (HMW) adiponectin, is recommended because of its positive association with cardiovascular fitness and insulin sensitivity and its negative association with the secretion of multiple proinflammatory cytokines. During caloric restriction, adiponectin levels increase disproportionately to
the decrease in FM. The multifunctional nature of adiponectin and its potentially pivotal role in mediating comorbidity risk make it a worthwhile and relatively inexpensive test to perform; analyses of high-molecular-weight and low-molecular-weight adiponectin is recommended in all studies (77,78).

Thyroid hormones
Measures of key components of thyroid hormones (thyroid-stimulating hormone, thyroxine (T4), and the free T4 Index) are recommended because of their known role in regulating energy balance. Diet-induced weight loss is accompanied by a decline in thyroid-stimulating hormone, Triiodothyronine (T3), and T4 similar to “sick euthyroid syndrome” (79,80), and thyroid-hormone repletion in weight-reduced individuals has recently been reported to resolve some of the peripheral adaptive responses thought to drive weight regain (Rosenbaum M, Goldsmith R, Haddad F, et al., unpublished data, 2018) in a manner similar to what is seen following thyroid repletion in hypothyroid individuals (81,82). Other factors commonly measured when assessing thyroid status (T3, reverse T3) present a significant burden for researchers because of the expense of these assays and are suggested only when resources are available.

Hunger/satiety signals
Hunger and/or satiety hormone levels change in response to meals and collectively provide surrogate signals for nutrient availability. A number of gut-derived peptides, including ghrelin, GLP-1, and PYY3-36, affect appetite (83) and coordinately change in response to calorie restriction (1). Baseline total ghrelin levels are predictive of weight loss (70), and meal responses of PYY3-36 and GLP-1 have been associated with successful reduced-weight maintenance (84). Such studies provide examples of how these peptides could be valuable in modeling treatment outcomes. Though postprandial responses of these hormones have provided the most pertinent information for predicting treatment responses, meal challenges were judged as too great of a burden on both participants and the researchers. The measurement of fasting total ghrelin, GLP-1, and PYY3-36 is recommended for all weight-loss studies as the best compromise between feasibility and informational value. Other gut peptides with similar actions were considered for predicting treatment outcomes, including cholecystokinin and glucagon inhibitory peptide, but the added value was deemed insufficient because of the greater assay difficulty and expense and the likelihood of collinearity with those already recommended. Plasma AgRP has been suggested as a biomarker of hypothalamic melanocortin activity, which could reflect downstream activity of the hunger and satiety signals even though there is only limited evidence for it as a biomarker. AgRP is linked to insulin sensitivity during and after weight loss (85), suggesting that this molecule may provide insights relevant to other biomarkers as well as brain function. For these reasons, measures of cholecystokinin, glucagon inhibitory peptide, AgRP, and postprandial responses of all of these hunger/satiety signals were suggested only when it is feasible and resources are available. It should also be noted that properly processed and stored samples can be biobanked (see below) for future analyses if cost limitations are prohibitive in a given study.

Nutrient status
Nutrient-sensing systems in peripheral tissues and in specific regions of the hypothalamus exist that convey signals of nutrient availability for appetite regulation and, therefore, serve as indices of nutrient status. Fasting levels of glucose, nonesterified fatty acids (NEFA), and triglycerides (TG) are recommended at baseline, during weight loss, and after weight loss. Glucose, NEFA, and TG are the primary nutrients in circulation, and all three respond to calorie-restricted weight loss (1). TG are also thought to affect the sensitivity of the brain to peripheral hormones through their effects on blood brain barrier transport. These metabolites consistently change with diet-induced weight loss in a manner that could elevate appetite (1), and the assays are relatively inexpensive and commonly used in clinical research. As with the gut peptides, the measuring postprandial responses of these molecules is not feasible in all studies. For these reasons, acquiring postprandial responses in glucose, NEFA, and TG is suggested only when resources are available.

Metabolic function
Metabolic (anabolic and catabolic) function, insulin sensitivity, and glucose control (recommended) could serve as mediators or moderators of treatment responses and have been shown to influence patterns of weight loss and weight-loss maintenance (71,86). Some studies have suggested that diet macronutrient content may influence weight-loss intervention efficacy according to the level of insulin sensitivity (87). The group recommends that fasting levels of insulin, glucagon, and glycosylated hemoglobin (HbA1c) be measured before, during, and after weight loss. Along with the metabolite data, these measures can be utilized to calculate indices of insulin sensitivity and secretion (homeostatic model assessment of insulin resistance and homeostatic model assessment for β-cell function; HOMA-IR, HOMA-β recommended) (88). There was some discussion that an oral glucose tolerance test should also be included to provide a more accurate assessment of glucose control. However, there was insufficient evidence that the oral glucose tolerance test would provide sufficient added value over the other surrogate biomarkers of metabolic function for weight-loss outcomes, and it is suggested only when resources are available. There are more invasive measures of insulin secretion and sensitivity (hyperinsulinemic-euglycemic clamp, intravenous glucose tolerance test, etc.) and more comprehensive measures of key aspects of metabolic flexibility, but these tests are not feasible for all large-scale clinical weight-loss trials.

Inflammation
We also recommend assessment of the inflammatory markers tumor necrosis factor-alpha, C-reactive protein, and interleukin 6 (IL-6) in the fasted state before, during, and after weight loss. These inflammatory factors could mediate or moderate the impact of metabolic dysfunction on treatment outcomes. Tumor necrosis factor-alpha is a true adipokine and is elevated in obesity (89). C-reactive protein is made in the liver, largely in response to IL-6, which is produced in liver and skeletal muscle. These molecules represent three different sources of inflammatory markers and are all associated with the subsequent risk for type 2 diabetes (90) and cardiovascular disease (91). By using network modeling that combined biological, gut microbiota, and environmental factors relevant to weight trajectories, baseline levels of IL-6 and plasma insulin most accurately classified individuals who did or did not lose weight and maintain weight loss (92). The global inflammatory status could be assessed by larger panels, but these biomarkers should be sufficient at present to examine the strength of the link between inflammation and treatment outcomes.
Biobanking Tissues

The molecular mechanisms underlying the physiological opposition to weight loss and reduced weight maintenance (2), and the possibility that they mimic the “preobesity” state in which someone is genetically and physiologically “at risk” for weight gain, have not been comprehensively elucidated. A uniform methodology across weight-loss studies for collecting and storing biological samples to measure RNA and DNA from cells in the blood as well as exosomal and free RNAs would provide a valuable resource for interrogating the molecular underpinnings of weight gain, weight loss, and weight regain. For reasons discussed below, biobanking of whole blood and its components (plasma, serum, etc.) with appropriate stabilization (e.g., protease inhibitors) is recommended as the best balance of feasibility, cost, participant burden, expertise and/or equipment needed to collect and process the samples, and relevance to weight-loss physiology.

Whole Blood

Though many different kinds of bodily fluids and tissues can be collected with varying degrees of difficulty, expense, and value (Figure 1), whole blood gives the greatest advantages for ease and the potential amount of relevant information it can provide. Though sample collection is invasive and can be challenging for individuals with obesity, participant burden and the need for expertise to collect whole blood samples is offset by the ability to use samples to interrogate circulating proteins, metabolites, and noncoding RNAs, which have been identified as relevant to energy homeostasis or which may one day be identified. In addition, both red and white cells can be used to examine cellular processes related to a host of outcomes, including glycosylation, immune response, and metabolism.

Functional Analysis/Genetic Screening

In addition to the assessment of the biomarkers described above, both RNA and DNA can be extracted from whole blood for a global assessment of genomic variation, gene expression, and epigenetic modification to ultimately allow a uniform characterization of the contribution of genes across weight-loss studies. This genetic screening would comprise a powerful resource for understanding the genetic and epigenetic molecular underpinnings of variability in weight loss. This type of screening is suggested at present because of resource limitations, but, as its feasibility and cost becomes more reasonable, we fully expect that it will become a recommended assessment. The biobanking recommendation of whole blood will

---

| Sample Type | Average Collection Cost | Difficulty of Collection | Need for Expertise/Equipment | Subject Burden | Range of Markers Measured | Relevance to Multiple Biological Processes | Average Rating | Comments |
|-------------|-------------------------|--------------------------|-------------------------------|---------------|--------------------------|-------------------------------------------|----------------|----------|
| Whole Blood |                         |                          |                               |               |                          |                                           |                |          |
| Buccal Cells|                         |                          |                               |               |                          |                                           |                |          |
| Urine       |                         |                          |                               |               |                          |                                           |                |          |
| Feces       |                         |                          |                               |               |                          |                                           |                |          |
| Saliva      |                         |                          |                               |               |                          |                                           |                |          |
| Tissue Biopsy|                        |                          |                               |               |                          |                                           |                |          |

Figure 1 Review of selection criteria for different tissues that could be biobanked. Whole blood is clearly the best fit for these criteria, though other tissues should not be eliminated if available depending upon their relevance to the specific study. Collection costs include creation of sample aliquots; measured markers include metabolites, nucleotides, and proteins.
### TABLE 1 Selected characteristics of recommended core measures for the ADOPT biological domain

| Logistics | Main evidence sourcesa | Suggested additional measures |
|-----------|------------------------|------------------------------|
| **Whole body assessments** | C, L, RCT |  |
| **Anthropometry** | Equipment, trained technician |  |
| Height, weight, and BMI; waist-to-hip ratio; waist circumference | Technician | NA | ~5 | B, MA | **DXA, MRI, QMRS** |
| **Anatomic fat storage (FM, FFM, visceral fat)** | Equipment, trained technician | C, L, RCT | **DLW, VO2, VO2** (calorimetry) |
| Bioelectrical impedance spectroscopy (BIS) | Technician | NA | 0 | **DXA, MRI, QMRS** |
| **Expended energy (EE)** | NA | C, L | **VO2, VO2** (calorimetry) |
| REE–Mifflin-St. Jeor equation, total EE | Calculated | NA | 0 | B, MA | **DLW** |
| **EE-activity** | Questions | 2 | <5 | **DLW** |
| Physical Activity Level (PAL) | Equipment, trained technician | C, L, RCT | **VO2, VO2** (calorimetry) |
| Total EE, steady state and change over time | Calculated | NA | 0 | B, MA | **DLW** |
| **Cardiorespiratory fitness (CRF)** | Equipment, trained technician | C, L, RCT | 3-minute step test |
| Resting heart rate | Interviewer | NA | 1 | **3-minute step test** |
| **Brain structure and function** | Equipment, trained technician | C, L | **3-minute step test** |
| Resting state fMRI; fed and fasted fMRI | Technician | NA | B | C, L | **3-minute step test** |
| **Blood biomarkers** | Equipment, trained technician | C, L | **3-minute step test** |
| **Blood homeostasis** | Equipment, trained technician | C, L | **3-minute step test** |
| Adiponectin, leptin, amylin | Blood | NA | Single blood | Phlebotomist | C, L, RCT |
| TSH, T4, IT4i (panel) | Blood | NA | **T3, rT3** |
| Glucagon-like peptide 1 (GLP-1), PYY3-36 (panel) | Blood | NA | CCK, GIP, AgRP, postprandial responses of ghrelin, GLP-1, and PYY |
| **Hunger/satiety** | Blood | NA | **T3, rT3** |
| Ghrelin, GLP-1, PYY3-36 (panel) | NA | 0 | **T3, rT3** |
| **Nutrient status** | Blood | NA | **T3, rT3** |
| Metabolite panel (glucose, NEFA, TG) | Blood | NA | **T3, rT3** |
| **Metabolic function** | Blood | NA | **T3, rT3** |
| Insulin, glucagon | Blood | NA | **T3, rT3** |
| Insulin sensitivity: HOMA-IR, HOMA-β | Blood | NA | **T3, rT3** |
| **Metabolic function** | Blood | NA | **T3, rT3** |
| Glucose control: HbA1c | Blood | NA | **OGTT** |
| **Inflammation** | Blood | NA | **OGTT** |
| IL-6, TNF-alpha, CRP | Blood | NA | **OGTT** |
| **Biobanking tissues** | Blood | NA | **OGTT** |
| **Buccal, saliva, urine, stool** | Blood | NA | **OGTT** |
| **Biobanking** | Blood | NA | **OGTT** |
| Whole blood | Blood | NA | **OGTT** |
| **Genetic screening** | Phlebotomist | C, L | **OGTT** |
| Whole blood | Blood | NA | **OGTT** |
| **BDNF, DRB3, FTO, GNPDA2, LYPL, MC4R, MTCH2, MTIF3, NEGR1, PLIN, RANK, LEP, LEPR** | Phlebotomist | C, L | **OGTT** |

**Italic font indicates objective measure.**

Evidence included both weight-related outcomes (e.g., weight loss) and weight-related behaviors (e.g., physical activity).

SA, self-administered; B, baseline; MA, multiple assessments across the trial; F, follow-up; C, cross-sectional; L, longitudinal; RCT, randomized controlled trial; BIS, bioelectrical impedance spectroscopy; DXA, dual energy x-ray absorptiometry; MRI, magnetic resonance imaging; QMRS, quantitative magnetic resonance; DLW, doubly labeled water; GLP-1, glucagon-like peptide 1; PYY3-36, peptide YY; TSH, thyroid-stimulating hormone; T4, thyroxine; IT4i, free T4 index; T3, triiodothyronine; rT3, reverse T3; CRP, C-reactive protein; IL-6, interleukin-6; TNF, tumor necrosis factor; FM, fat mass; FFM, fat-free mass; HOMA-IR, homeostatic model assessment of insulin resistance; HOMA-β, homeostatic model assessment for β-cell function; NEFA, nonesterified fatty acids; TG, triglycerides.
ensure that tissues will be available to pursue future genetic studies, even if resources are not immediately available. Sequence variations in multiple genes have been tied to energy balance and treatment outcomes in weight-loss studies, which could serve to focus the analysis. These genes include $BDNF$, $DRB3$, $FTO$, $GNPDA2$, $LYPLA$, $MC4R$, $MTCH2$, and $MTIF3$, while other less-studied genes ($NEGR1$, $PLIN$, and $RANK$, $LEP$ and $LEPR$) may also provide relevant information about the variability in treatment response. Studies demonstrating significant intrapair correlations ($r = 0.75-0.85$) in response to weight-loss interventions among identical twins (93) and genetic predictors of weight-loss response to various interventions in large clinical trials (94,95) suggest that different single-nucleotide polymorphisms (SNPs) may be predictive of the magnitude of weight loss versus regain depending upon the nature of the intervention and subject population. In the future, the use of array-based chips with highly informative dense SNP content, including genome-wide tag SNPs found across diverse world populations and customizable markers for use in large weight-loss studies, can be used as a cost-effective means of creating a well-powered cohort of individuals in which the genetic underpinnings of weight loss can be examined for multiple traits and outcomes.

Other Tissue Considerations

Biobanking of other tissues is also suggested depending upon resource availability. Buccal (cheek) cells (suggested) are easy and inexpensive to collect via cytobrushes, which involves simply swabbing the cheeks and gutters of the mouth to collect sloughed cells. Both DNA and RNA can be extracted from buccal cells (96), though there is a limited range and relevance of markers that can be measured (96). Similar limitations are inherent in the use of saliva samples (suggested). Urine and stool samples (suggested) are relatively easy and inexpensive to obtain, though the relevance of urinary biomarkers to weight loss may be limited. Stool (97) can be used to examine the gut microbiome, gut absorption, and markers of metabolism. Although transplantation of the microbiome from obese or lean mice or humans to gnotobiotic (germ-free mice) clearly affects somatotype, the role of the microbiome as a cause or potential therapeutic target in human obesity is not clearly established (98). Current research in the NIH Human Microbiome Project (HMP) (99) directly addresses these issues, and investigators are suggested to contact the NIH directly for microbiome banking information.

Tissue biopsies allow for the unbiased genomic, epigenetic, and proteomic interrogation of key metabolic tissues (skeletal muscle, adipose) involved in the regulation of energy balance. Because of the burdens placed on subjects and investigators, the collection of specific tissue biopsies is suggested for studies with specific objectives directed at elucidating molecular mechanisms or generating the evidence as to how these tissues could serve as mediators or moderators of treatment outcomes.

Conclusions

The ADOPT biological domain subgroup was tasked with identifying feasible measures of biological constructs (body composition, energy homeostasis, brain structure and function, blood biomarkers, and biobanking tissues) that, when used consistently in weight-loss trials, could serve to explain the variability in treatment outcomes and lay the foundation for genetic-, epigenetic-, and genomic-based analyses. Selections (Table 1) were made with the underlying goal of maximizing the potential to address knowledge gaps in obesity treatment in conjunction with the other ADOPT domains. It is the intent of the ADOPT project that these recommendations and suggestions as well as the GEM website will be updated as new information becomes available.

It should be emphasized that the recommended measures are not always the “gold standard,” but they are the ones that are most feasible across numerous different study sizes and population. When integrated across studies and with the other ADOPT domains, the recommended measures will facilitate the development of a large comprehensive database that could be mined to evaluate, propose, and implement current and future obesity treatments with maximal efficacy. The recommended and suggested measures are intended to augment weight-loss intervention studies rather than replace planned measures.

The strengths and weaknesses of the ADOPT biological domain are closely intertwined. The main strength is the practicality of the measures that can be implemented in most, if not all, studies going forward at little additional expense and inconvenience to investigators and participants. An additional strength is the intentional malleability of the ADOPT recommendations and suggestions. Regular modifications of the ADOPT domain manuscripts are anticipated based on new data and techniques that become available and on input from the scientific community through the GEM website. The weaknesses of the recommended and suggested measures are that, to achieve necessary fiscal and feasibility goals, numerous more sensitive or specific measures are not included. To address these issues, we would encourage biobanking of serum, plasma, and buffy coats on as many participants as possible in anticipation of the decreasing costs and increasing understanding of relevant future assays.

Acknowledgments

The authors gratefully acknowledge the assistance of Drs. Dympna Gallagher and Judith Korner at Columbia University Medical Center for their assistance in clarifying and better delineating some of the body composition and biomarker measures.

References

1. Maclean P, Bergouignan A, Cornier M, Jackman M. Biology’s response to dieting: the impetus for weight regain. Amer J Regul Integr Physiol 2011;301:R581-R600.
2. Leibel R, Rosenbaum M. Metabolic response to weight perturbation. In: Clément K, ed. Novel Insights into Adipose Cell Functions, Research and Perspectives in Endocrine Interactions. Heidelberg: Springer-Verlag; 2010: 121-33.
3. Leibel R, Rosenbaum M, Hirsch J. Changes in energy expenditure resulting from altered body weight. N Eng J Med 1995;332:621-628.
4. Manning S, Pucci A, Carter N, et al. Early postoperative weight loss predicts maximal weight loss after sleeve gastrectomy and Roux-en-Y gastric bypass. Surg Endosc 2015;29:1484-1491.
5. Smith S, Prosser W, Donajue D, Morgan M, Anderson C, Shanahan W, Lorcanerin (APD356), a selective 5-HT(2C) agonist, reduces body weight in obese men and women. Obesity (Silver Spring) 2009;17:494-503.
6. Look AHEAD Research Group; Wadden T, Neiberger R, Wing R, et al. Four-year weight losses in the Look AHEAD study: factors associated with long-term success. Obesity (Silver Spring) 2011;19:1987-1998.
7. Schwartz M, Boyko E, Kahn S, Ravussin E, Bogardus C. Reduced insulin secretion: an independent predictor of body weight gain. J Clin Endocrinol Metab 1995;80:1571-1576.
8. MacLean PS, Rothman AJ, Nicoastro HL, et al. The Accumulating Data to Optimally Predict obesity Treatment (ADOPT) Core Measures Project: rationale and approach. *Obesity (Silver Spring)* 2018;26(suppl 2):S5-S15.

9. MacLean P, Wing R, Davidson T, et al. NHF working group report: innovative research to improve maintenance of weight loss. *Obesity (Silver Spring)* 2015;23:7-15.

10. Look AHEAD Research Group; Unick J, Beavers D, Jakicic J, et al. Effectiveness of lifestyle interventions for individuals with severe obesity and type 2 diabetes: results from the Look AHEAD trial. *Diabetes Care* 2013;34:2152-2157.

11. Wise E, Felton J, Kligman M. Exponential decay modeling can define parameters of fat loss irreversibly after laparoscopic Roux-en-Y gastric bypass. *Am J Surg* 2017:9610:31328-31334.

12. Nikolic M, Knijilc I, Kirigin L, et al. Initial weight loss after restrictive bariatric procedures may predict mid-term weight maintenance: results from a 12 month pilot trial. *Bariatr Surg Pract Patient Care* 2015;10:68-73.

13. Look AHEAD Research Group; Unick J, Neiberg R, Hogan P, et al. Weight change in the first 2 months of a lifestyle intervention predicts weight changes 8 years later. *Obesity (Silver Spring)* 2015;23:1353-1356.

14. Hadziahmeti M, Mucalo I, Harbac P, Matic T, Rahelic D, Boziko V. Factors predictive of drop-out and weight loss success in weight management of obese patients. *J Hum Nutr Diet* 2015;28(suppl 2):24-32.

15. Bergman R, Stefanovski D, Buchanan T, et al. A better index of body adiposity. *Obesity (Silver Spring)* 2011;19:1083-1089.

16. Wang N, Hikida RS, Staron RS, Simooneau J. Muscle fiber types of women after resistance training- quantitative ultrastructure and enzyme activity. *Pflugers Arch* 1993;424:494-502.

19. SK Finn MI, Karastergiou. Shaping fat distribution: new insights into the molecular determinants of depot- and sex-dependent adipose biology. *Obesity (Silver Spring)* 2015;23:1345-1352.

20. Pouliot M, Despres J, Lemieux S, et al. Waist circumference and abdominal sagittal diameter: best simple anthropometric indexes of abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and women. *Am J Cardiol* 1994;73:460-468.

21. Larsson B, Svarsudd K, Welin L, Wilhelmsen L, Bjorntorp P, Tibblin G. Abdominal adipose tissue distribution, obesity, and risk of cardiovascular disease and death: 13 year follow up of participants in the study of men born in 1913. *Br Med J* 1984;288:1041-1044.

22. Lapidus L, Bengtsson C, Larsson B, Pennert K, Rybo E, Sjostrom L. Distribution of adipose tissue and risk of cardiovascular disease and death: a 12 year follow up of participants in the population study of women in Gothenburg, Sweden. *Br Med J* 1998;316:1189-1192.

23. Tchernev A, Despres JP. Pathophysiology of human visceral obesity: an update. *Physiol Rev* 2013:93:359-404.

24. Bosy-Westphal A, Kahlhofer L, Lagerpusch M, Skurk T, Muller M. Deep body MRI with generally used anthropometric data. *Invest Radiol* 2015:56:28-33.

25. Ludescher B, Machann J, Eschweiler G, et al. Correlation of fat distribution in whole body MRI with generally used anthropometric data. *Br J Radiol* 2014:68:581-586.
63. Park B, Soo J, Park H. Functional brain networks associated with eating behaviors in obesity. *Sci Rep* 2016;31:23891. doi: 10.1038/srep23891

64. Wright H, Xiaoyuan L, Fallon N, et al. Differential effects of hunger and satiety on insular cortex and hypothalamic functional connectivity. *Eur J Neurosci* 2016;43:1181-1189.

65. Garcia-Garcia I, Jurado M, Garolero M, et al. Alterations of the salience network in obesity: a resting state MRI study. *Hum Brain Mapp* 2013;34:2788-2797.

66. Kullmann S, Heni M, Velt R, et al. The obese brain: association of body mass index and insulin sensitivity with resting state network functional connectivity. *Hum Brain Mapp* 2012;33:1052-1061.

67. Chen S, Dong D, Jackson T, Zhuang Q, Chen H. Trait-based food cravings are encoded by regional homogeneity in the parahippocampal gyrus. *Appetite* 2017;114:115-160.

68. Action in Health in Diabetes Brain Magnetic Resonance Imaging Look AHEAD Brain Ancillary Study Research Group; Casanova R, Hayasaka S, Saldana S, et al. Relative differences in resting-state brain connectivity associated with long-term intensive lifestyle intervention. *Psychoneuroendocrinol* 2016;74:231-239.

69. Lepping R, Bruce A, Grancisco J, et al. Resting state brain connectivity after surgical and behavioral weight loss. *Obesity (Silver Spring)* 2015;23:1422-1428.

70. Crujeiras A, Goyenechea E, Abete I, et al. Weight regain after a diet-induced loss of weight: a long-term follow-up of a randomized controlled trial. *Nutr Metab* 2011;8:50.

71. Couroucles A, Christian M, O’Rourke R, et al. Preoperative factors and 3-year weight change in the Longitudinal Assessment of Bariatric Surgery (LABS) consortium. *Surg Obes Relat Dis* 2015;11:1109-1118.

72. Strohacker K, McCaffery J, MacLean P, Wing R. Adaptations of leptin, ghrelin, or omentin during weight loss as predictors of weight regain: a review of current literature. *Int J Obes* 2014;38:388-396.

73. Rosenbaum M, Leibel R. 20 years of leptin: role in the homeostatic and hedonic control of eating and recent developments of amylin analogs to treat obesity. *Metabolism* 2016;71:203-210.

74. Hay D, Chen S, Lutz T, Parkes D, Roth J. Amylin and its role in the homeostatic and hedonic control of eating and recent developments of amylin analogs to treat obesity. *Mol Metab* 2017;8:203-210.

75. Ravussin E, Smith S, Mitchell J, et al. Evaluation of CSF and plasma biomarkers of brain melanin gene activity in response to low caloric restriction in humans. *Am J Physiol Endocrinol Metab* 2017;312:E19-E26.

76. Look AHEAD Study Group; Espeland M, Bray G, Neiberg R, et al. Describing patterns of weight changes using principal components analysis: results from the Action for Health in Diabetes (Look AHEAD) research group. *Am Epidemiol* 2009;19:701-710.

77. Cornier M, Donahoo W, Pereira R, et al. Insulin sensitivity determines the effectiveness of dietary macronutrient composition on weight loss in obese women. *Obes Rev* 2005;13:703-709.

78. Montejo M, Battenham R. The importance of the gastrointestinal tract in controlling food intake and regulating energy balance. *Gastroenterol* 2017;152:1707-1717.

79. Rosenbaum M, Basdevant A, Fatás E, et al. Evaluation of the associations between plasma biomarkers of brain melanin gene activity and weight loss maintenance: results from the Action for Health in Diabetes (Look AHEAD) research group. *Hum Genet* 2012;85:1201-1209.

80. Rosenbaum M, Leibel R. The microbiome in obesity. *Trends Endocrinol Metab* 2015;26:493-501.

81. Montejo M, Battenham R. The importance of the gastrointestinal tract in controlling food intake and regulating energy balance. *Gastroenterol* 2017;152:1707-1717.

82. Page-Wilson G, Nguyen K, Atalayer D, et al. Evaluation of CSF and plasma biomarkers of brain melanin gene activity in response to low caloric restriction in humans. *Am J Physiol Endocrinol Metab* 2017;312:E19-E26.

83. Look AHEAD Study Group; Espeland M, Bray G, Neiberg R, et al. Describing patterns of weight changes using principal components analysis: results from the Action for Health in Diabetes (Look AHEAD) research group. *Am Epidemiol* 2009;19:701-710.

84. Cornier M, Donahoo W, Pereira R, et al. Insulin sensitivity determines the effectiveness of dietary macronutrient composition on weight loss in obese women. *Obes Rev* 2005;13:703-709.

85. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. *Diabetologia* 1985;28:412-419.

86. Moller K, Ostermann AI, Rund K, et al. Influence of weight reduction on blood levels of C-reactive protein, tumor necrosis factor-a, interleukin-6, and otrylins in obese subjects. *Prostaglandins Leukot Essent Fatty Acids* 2016;106:39-49.

87. Rosenbaum M, Basdevant A, Fatás E, et al. Evaluation of the associations between plasma biomarkers of brain melanin gene activity and weight loss maintenance: results from the Action for Health in Diabetes (Look AHEAD) research group. *Hum Genet* 2012;85:1201-1209.

88. Rosenbaum M, Basdevant A, Fatás E, et al. Evaluation of the associations between plasma biomarkers of brain melanin gene activity and weight loss maintenance: results from the Action for Health in Diabetes (Look AHEAD) research group. *Hum Genet* 2012;85:1201-1209.

89. Rosenbaum M, Basdevant A, Fatás E, et al. Evaluation of the associations between plasma biomarkers of brain melanin gene activity and weight loss maintenance: results from the Action for Health in Diabetes (Look AHEAD) research group. *Hum Genet* 2012;85:1201-1209.

90. Rosenbaum M, Basdevant A, Fatás E, et al. Evaluation of the associations between plasma biomarkers of brain melanin gene activity and weight loss maintenance: results from the Action for Health in Diabetes (Look AHEAD) research group. *Hum Genet* 2012;85:1201-1209.

91. Rosenbaum M, Basdevant A, Fatás E, et al. Evaluation of the associations between plasma biomarkers of brain melanin gene activity and weight loss maintenance: results from the Action for Health in Diabetes (Look AHEAD) research group. *Hum Genet* 2012;85:1201-1209.

92. Rosenbaum M, Basdevant A, Fatás E, et al. Evaluation of the associations between plasma biomarkers of brain melanin gene activity and weight loss maintenance: results from the Action for Health in Diabetes (Look AHEAD) research group. *Hum Genet* 2012;85:1201-1209.

93. Rosenbaum M, Basdevant A, Fatás E, et al. Evaluation of the associations between plasma biomarkers of brain melanin gene activity and weight loss maintenance: results from the Action for Health in Diabetes (Look AHEAD) research group. *Hum Genet* 2012;85:1201-1209.

94. Rosenbaum M, Basdevant A, Fatás E, et al. Evaluation of the associations between plasma biomarkers of brain melanin gene activity and weight loss maintenance: results from the Action for Health in Diabetes (Look AHEAD) research group. *Hum Genet* 2012;85:1201-1209.

95. Rosenbaum M, Basdevant A, Fatás E, et al. Evaluation of the associations between plasma biomarkers of brain melanin gene activity and weight loss maintenance: results from the Action for Health in Diabetes (Look AHEAD) research group. *Hum Genet* 2012;85:1201-1209.

96. Rosenbaum M, Basdevant A, Fatás E, et al. Evaluation of the associations between plasma biomarkers of brain melanin gene activity and weight loss maintenance: results from the Action for Health in Diabetes (Look AHEAD) research group. *Hum Genet* 2012;85:1201-1209.

97. Rosenbaum M, Basdevant A, Fatás E, et al. Evaluation of the associations between plasma biomarkers of brain melanin gene activity and weight loss maintenance: results from the Action for Health in Diabetes (Look AHEAD) research group. *Hum Genet* 2012;85:1201-1209.

98. Rosenbaum M, Basdevant A, Fatás E, et al. Evaluation of the associations between plasma biomarkers of brain melanin gene activity and weight loss maintenance: results from the Action for Health in Diabetes (Look AHEAD) research group. *Hum Genet* 2012;85:1201-1209.

99. Rosenbaum M, Basdevant A, Fatás E, et al. Evaluation of the associations between plasma biomarkers of brain melanin gene activity and weight loss maintenance: results from the Action for Health in Diabetes (Look AHEAD) research group. *Hum Genet* 2012;85:1201-1209.

100. Rosenbaum M, Basdevant A, Fatás E, et al. Evaluation of the associations between plasma biomarkers of brain melanin gene activity and weight loss maintenance: results from the Action for Health in Diabetes (Look AHEAD) research group. *Hum Genet* 2012;85:1201-1209.